Guideline adherence is associated with long-term all-cause mortality in patients after an acute coronary syndrome

Abstract Background/Introduction Guideline-directed medical therapy (GDMT) remains the mainstay in the long-term management of patients after an acute coronary syndrome (ACS). Data on the association of adherence to GDMT with clinical outcomes are scarce. Purpose To assess the adherence to GDMT and its relation to all-cause mortality in a population of patients after an ACS. Methods In this post-hoc analysis of the prospective, randomised IDEAL-LDL trial (NCT02927808) we analyzed data of 360 ACS patients discharged from a cardiology clinic. Median follow-up period was 35.9 (IQR 25.7–41.6) months. GDMT was assessed at discharge and at the 1-year follow-up, at which time data was collected by telephone interviews or ambulant visits. GDMT was defined as compliance with secondary prevention therapies (statin, antiplatelet, b-blocker, angiotensin-converting enzyme inhibitor (ACE-i) or angiotensin II receptor blocker (ARB)), as per their respective indication in the 2017 STEMI and 2015 NSTE-ACS ESC Guidelines. Extended follow-up data for mortality was collected from the national health insurance electronic prescription system. Results Median age of the entire cohort was 60 (IQR-53–71) years, 18.6% were female and 55.6% suffered a STEMI. At discharge, 342 patients (95%) received statins, 331 (91.9%) proper antithrombotic therapy (86.4% on dual antiplatelet therapy (DAPT), 2.5% on antiplatelet plus anticoagulant and 3% on triple therapy), 309 (85.8%) β-blockers and 217 (60.3%) ACE-i or ARB. GDMT at discharge was prescribed to 272 (75.6%) patients. The 1-year mortality rate was 4.7% (IQR, 2.5–6.9) and there was no mortality benefit for GDMT (HR=0.77 95% CI 0.27 - 2.2) (Figure 1a). At the one-year follow up, 323 (94.2%) of 343 alive patients received statin treatment (72.4% of which a high-intensity statin), 330 (96.2%) any antithrombotic therapy (59.8% on DAPT, 5.2% on any anticoagulant), 263 (76.7%) a β-blocker and 194 (56.6%) an ACE-I or ARB. GDMT at one-year follow up was prescribed to 248 (72.3%) patients. Beyond one year, all-cause mortality was significantly reduced in patients receiving GDMT adjusted for age, STEMI, revascularization with percutaneous coronary angioplasty, history of diabetes mellitus and arterial hypertension. (1.6% vs 9.5%, aHR 0.3 95% CI 0.08 - 0.92) (Figure 1b). Conclusions Adherence to GDMT remains stable one year after an ACS. GDMT was associated with a significant decrease in long-term mortality, but not associated with one-year mortality. Figure 1. GDMT at baseline, at 1 year and mortality Funding Acknowledgement Type of funding source: None

Download Full-text

High-Sensitivity Troponin T vs I in Acute Coronary Syndrome: Prediction of Significant Coronary Lesions and Long-term Prognosis

Clinical Chemistry ◽

10.1373/clinchem.2016.261107 ◽

2017 ◽

Vol 63 (2) ◽

pp. 552-562 ◽

Cited By ~ 15

Author(s):

Brede Kvisvik ◽

Lars Mørkrid ◽

Helge Røsjø ◽

Milada Cvancarova ◽

Alexander D Rowe ◽

...

Keyword(s):

Acute Coronary Syndrome ◽

Coronary Angiography ◽

High Sensitivity ◽

Coronary Syndrome ◽

Prognostic Accuracy ◽

All Cause Mortality ◽

Coronary Lesions ◽

Long Term Prognosis

Abstract BACKGROUND High-sensitivity cardiac troponin (hs-cTn) T and I assays are established as crucial tools for the diagnosis of acute myocardial infarction (AMI), as they have been found superior to old troponin assays. However, eventual differences between the assays in prediction of significant coronary lesions and long-term prognosis in patients with acute coronary syndrome (ACS) have not been fully unraveled. METHODS Serum concentrations of hs-cTnT (Roche), hs-cTnI (Abbott), and amino-terminal pro-B-type natriuretic peptide (NT-proBNP; Roche) in 390 non-ST-elevation (NSTE) ACS patients were evaluated in relation to significant coronary lesions on coronary angiography (defined as a stenosis >50% of the luminal diameter, with need for revascularization) and prognostic accuracy for cardiovascular mortality, all-cause mortality, as well as the composite end point of cardiovascular mortality and hospitalizations for AMI or heart failure. RESULTS The mean (SD) follow-up was 2921 (168) days. Absolute hs-cTnI concentrations were significantly higher than the hs-cTnT concentrations. The relationship between analyzed biomarkers and significant coronary lesions on coronary angiography, as quantified by the area under the ROC curve (AUC), revealed no difference between hs-cTnT [AUC, 0.81; 95% CI, 0.77–0.86] and hs-cTnI (AUC, 0.81; 95% CI, 0.76–0.86; P = NS). NT-proBNP was superior to both hs-cTn assays regarding prognostic accuracy for both cardiovascular and all-cause mortality and for the composite end point during follow-up, also in multivariate analyses. CONCLUSIONS The hs-cTnT and hs-cTnI assays displayed a similar ability to predict significant coronary lesions in NSTE-ACS patients. NT-proBNP was superior to both hs-cTn assays as a marker of long-term prognosis in this patient group.

Download Full-text

Association Between Metabolic Syndrome and All-Cause Mortality in Patients with Acute Coronary Syndrome: A Meta-Analysis

Hormone and Metabolic Research ◽

10.1055/a-1381-8245 ◽

2021 ◽

Author(s):

Yong Yang ◽

Haili Shen ◽

Zhigeng Jin ◽

Dongxing Ma ◽

Qing Zhao ◽

...

Keyword(s):

Metabolic Syndrome ◽

Acute Coronary Syndrome ◽

Hospital Mortality ◽

Meta Analysis ◽

Survival Outcome ◽

Coronary Syndrome ◽

Increased Risk ◽

All Cause Mortality

AbstractThe association between metabolic syndrome (MetS) and survival outcome after acute coronary syndrome (ACS) remains controversial. This meta-analysis sought to examine the association of MetS with all-cause mortality among patients with ACS. Two authors independently searched PubMed and Embase databases (from their inception to June 27, 2020) for studies that examined the association of MetS with all-cause mortality among patients with ACS. Outcome measures were in-hospital mortality and all-cause mortality during the follow-up. A total of 10 studies involving 49 896 ACS patients were identified. Meta-analysis indicated that presence of MetS was associated with an increased risk of long-term all-cause mortality [risk ratio (RR) 1.25; 95% CI 1.15–1.36; n=9 studies] and in-hospital mortality (RR 2.35; 95% CI 1.40–3.95; n=2 studies), respectively. Sensitivity and subgroup analysis demonstrated the credibility of the value of MetS in predicting long-term all-cause mortality. MetS is associated with an increased risk of long-term all-cause mortality among patients with ACS. However, additional studies are required to investigate the association of MetS with in-hospital mortality.

Download Full-text

Prognostic relevance of GRACE risk score in Takotsubo syndrome

European Heart Journal Acute Cardiovascular Care ◽

10.1177/2048872619882363 ◽

2019 ◽

Vol 9 (7) ◽

pp. 721-728 ◽

Cited By ~ 2

Author(s):

Fernando Scudiero ◽

Luca Arcari ◽

Luca Cacciotti ◽

Elena De Vito ◽

Rossella Marcucci ◽

...

Keyword(s):

Acute Coronary Syndrome ◽

Risk Score ◽

Takotsubo Syndrome ◽

Coronary Syndrome ◽

Grace Risk Score ◽

All Cause Mortality ◽

Long Term Follow Up ◽

Grace Score

Background: Takotsubo syndrome is an increasingly recognised cardiac condition that clinically mimics an acute coronary syndrome, but data regarding its prognosis remain controversial. It is currently unknown whether acute coronary syndrome risk scores could effectively be applied to Takotsubo syndrome patients. This study aims to assess whether the Global Registry of Acute Coronary Events (GRACE) score can predict clinical outcome in Takotsubo syndrome and to compare the prognosis with matched acute coronary syndrome patients. Methods: A total of 561 Takotsubo syndrome patients was included in this prospective registry. According to the GRACE score, the population was divided into quartiles. The primary endpoint was all-cause mortality and the secondary endpoints were cardiocerebrovascular events (a composite of all-cause mortality, cardiovascular death, recurrence of Takotsubo syndrome and stroke). Results: The median GRACE risk score was 139±27. Takotsubo syndrome patients with a higher GRACE risk score mostly have a higher rate of physical triggers and lower left ventricular ejection fraction on admission. During long-term follow-up, all-cause mortality rates were 5%, 11%, 12% and 22%, respectively, in the first, second, third and fourth quartile ( P<0.001). After multivariate analysis, the GRACE risk score was found to be a strong predictor of all-cause mortality (odds ratio (OR) 1.68, 95% confidence interval (CI) 1.28–2.20; P=0.001) and cardiocerebrovascular events (OR 1.63, 95% CI 1.26–2.11; P=0.001). Moreover, all-cause mortality in Takotsubo syndrome patients was comparable with the matched acute coronary syndrome cohort. Conclusion: In Takotsubo syndrome, the GRACE risk score allows us to predict all-cause mortality and cardiocerebrovascular events at long-term follow-up.

Download Full-text

P3613J-shaped relationship between cardiac mortality risk and admission systolic blood pressure in patients aged 65 years and over with acute coronary syndrome

European Heart Journal ◽

10.1093/eurheartj/ehz745.0472 ◽

2019 ◽

Vol 40 (Supplement_1) ◽

Author(s):

C Y Jiang ◽

H W Li

Keyword(s):

Blood Pressure ◽

Acute Coronary Syndrome ◽

Systolic Blood Pressure ◽

Cardiac Death ◽

Cardiac Mortality ◽

Coronary Syndrome ◽

Kaplan Meier ◽

All Cause Mortality

Abstract Objective To observe the effects of different admission systolic blood pressure (SBP) levels on the in-hospital and long-term prognosis of elderly patients with acute coronary syndrome (ACS). Methods This retrospective cohort study included 5812 ACS patients aged 65 and over admitted from January, 2013 to September, 2018. Their blood pressure, medical history and laboratory examinations were recorded. The patients were divided into 5 groups according to the level of admission SBP (<100, 100–119, 120–139, 140–159, and ≥160 mmHg). The main endpoint of this study was cardiac death and all-cause death in hospital and during 6-year follow-up. Results Among the participants, the number of patients admitted with SBP <100, 100–119, 120–139, 140–159, and ≥160 mmHg were 143 (2.5%), 1014 (17.4%), 2456 (42.3%), 1607 (27.6%), and 592 (10.2%), respectively. The highest in-hospital cardiac mortality and all-cause mortality rate were found in the group with admission SBP <100 mmHg and the lowest were found in the group with SBP 140–159 mmHg (9.1% vs. 3.2% vs. 1.1% vs. 0.8% vs. 1.5%, P=0.000; 9.8% vs. 3.4% vs. 1.1% vs. 0.8% vs. 1.7%, P=0.000). Kaplan-Meier curve showed that patients with SBP 120–139 mmHg at admission had better prognosis (cardiac mortality: 3.9% vs. 10.9%, 5.6%, 5.1%, and 6.7% respectively, P=0.000; all-cause mortality: 7.6% vs. 14.7%, 9.7%, 9.1%, and 11.0%, respectively, P=0.000). Multivariate analysis showed that admission SBP <120 mmHg or ≥160 mmHg was a independent predictors of follow-up cardiac death (HR 1.747, 95% CI 1.066–2.861, P=0.027; HR 1.496, 95% CI 1.092–2.050, P=0.012; HR 1.630, 95% CI 1.120–2.372, P=0.011) compared with patients admitted with SBP 120–139 mmHg. In-hospital and 6-year follow-up outcomes of ACS patients ≥65y by admission SBP Admission SBP Level <100mmHg ≥100mmHg and <120mmHg ≥120mmHg and <140mmHg ≥140mmHg and <160mmHg ≥160mmHg P In-hospital (n=143) (n=1014) (n=2456) (n=1607) (n=592) Cardiac mortality, n (%) 13 (9.1) 32 (3.2) 28 (1.1) 13 (0.8) 9 (1.5) 0.000 All-cause mortality, n (%) 14 (9.8) 34 (3.4) 28 (1.1) 13 (0.8) 10 (1.7) 0.000 Follow-up (n=129) (n=980) (n=2428) (n=1594) (n=582) Cardiac mortality, n (%) 14 (10.9) 55 (5.6) 94 (3.9) 81 (5.1) 39 (6.7) 0.000 All-cause mortality, n (%) 19 (14.7) 95 (9.7) 185 (7.6) 144 (9.1) 64 (11.0) 0.000 Kaplan-Meier analyses Conclusion In ACS patients ≥65 y, a “J” relationship between admission SBP and cardiac mortality is observed. For ACS patients aged 65 years and over, admission SBP <120 mmHg or ≥160mmHg is a independent risk factor for long-term cardiac death. Acknowledgement/Funding National Natural Science Foundation of China (No. 81300333))

Download Full-text

P5368The prevalence and management of familial hypercholesterolemia in patients with acute coronary syndrome in Poland: results of the TERCET registry

European Heart Journal ◽

10.1093/eurheartj/ehz746.0333 ◽

2019 ◽

Vol 40 (Supplement_1) ◽

Author(s):

K Dyrbus ◽

M Gasior ◽

P Desperak ◽

J Nowak ◽

T Osadnik ◽

...

Keyword(s):

Acute Coronary Syndrome ◽

Propensity Score ◽

Propensity Score Matching ◽

Familial Hypercholesterolemia ◽

Lipid Lowering ◽

Propensity Score Matching Analysis ◽

Coronary Syndrome ◽

All Cause Mortality

Abstract Background Prevalence of familial hypercholesterolemia (FH) is high among patients with coronary artery disease (CAD). However, data on FH among patients with acute coronary syndrome (ACS) are still scarce. Purpose Therefore, we aimed to assess the prevalence, lipid-lowering therapy and short- and long-term outcomes in patients with FH among patients with ACS. Methods We finally included 19,582 consecutive patients from the Hyperlipidaemia Therapy in the tERtiary Cardiological cEnTer (TERCET) Registry for years 2006–2018. Among them, there were 7,319 patients admitted with ACS: 3,085 due to ST-segment elevation acute coronary syndrome (STEMI), 2,256 due to NSTEMI, and 1,978 due to unstable angina (UA). Stable CAD [sCAD] group n=12,462 that was treated as a reference one. Based on the personal and familial history of premature cardiovascular disease and low-density lipoprotein cholesterol (LDL-C) concentration, the Dutch Lipid Clinic Network (DLCN) algorithm was used for FH diagnosis. Results At the time of hospitalization, the overall occurrence of probable/definite FH and possible FH were 1.2% and 13.5% respectively. In patients with ACS, 1.6% had probable/definite FH and 17.0% possible FH. The highest occurrence of FH was observed in STEMI subgroup, where 20.6% of the patients had ≥3 points according to the DLCN criteria. There were significant differences in hypolipemic treatment between the FH subpopulations. In patients with definite/probable FH 92.3% and 91.5% were administered statins at discharge, respectively (including 52.9% prescribed intensive statin therapy). Patients with definite and probable FH had higher 30-day mortality than patients without FH (8.2% and 3.8% vs 2.0%, respectively; p=0.0052). However, no significant differences were observed between the FH groups in the 12-, 36- and 60-month follow-up (Figure). Propensity-score matching analysis showed that definite/probable FH patients had significantly higher all-cause mortality at the 36- and 60-month follow-up in comparison to non-FH subjects (11.4% vs 4.8% and 19.2% vs 7.2%, respectively; p≤0.021 for both). Outcomes depending on DCLN FH diagnosis. Conclusions The prevalence of FH according to the DLCN criteria in the Polish very high-risk population is even 14.7% and is significantly higher in patients with ACS than in patients with sCAD. Among patients included in the Registry, the occurrence of FH rises to 20.6% in the STEMI subgroup, and to 17.2% in the NSTEMI subgroup. Propensity-score matching analysis confirmed that FH itself is a cause of increased all-cause mortality in the long-term follow-up. Acknowledgement/Funding None

Download Full-text

Short-term and long-term prognostic value of circulating soluble suppression of tumorigenicity-2 concentration in acute coronary syndrome: a meta-analysis

Bioscience Reports ◽

10.1042/bsr20182441 ◽

2019 ◽

Vol 39 (6) ◽

Author(s):

Linlin Gu ◽

Jing Li

Keyword(s):

Acute Coronary Syndrome ◽

Prognostic Value ◽

Meta Analysis ◽

Continuous Variables ◽

Short Term ◽

Coronary Syndrome ◽

Increased Risk ◽

All Cause Mortality

Abstract Background: Higher circulating soluble suppression of tumorigenicity-2 (sST2) concentration is suggested as a marker of prognosis in many cardiovascular diseases. However, the short-term and long-term prognostic value of sST2 concentration in acute coronary syndrome (ACS) remains to be summarized. Methods: A meta-analysis of follow-up studies was performed. Studies were identified via systematic search of databases including PubMed, Cochrane’s Library, and Embase. A fixed- or random-effect model was applied according to the heterogeneity. We reported the prognostic value of sST2 concentration for all-cause mortality, heart failure (HF) events, and major adverse cardiovascular events (MACEs) within 1 month after hospitalization and during subsequent follow-up. Results: Twelve studies with 11690 ACS patients were included. Higher baseline sST2 concentration as continuous variables predicte the increased risk of all-cause mortality (risk ratio [RR]: 3.16, P=0.002), HF events (RR: 1.48, P<0.001), and MACEs (RR: 1.47, P<0.001) within 1 month after hospitalization, which is consistent with the results with sST2 concentration as categorized variables (RR = 2.14, 2.89, and 2.89 respectively, P all <0.001). Moreover, higher baseline sST2 concentration as continuous variables predict the increased risk of all-cause mortality (RR: 2.20, P<0.001), HF events (RR: 1.39, P<0.001), and MACEs (RR: 1.53, P=0.02) during subsequent follow-up. Meta-analysis with sST2 concentration as categorized variables retrieved similar results (RR = 2.65, 2.59, and 1.81 respectively, P all <0.001). Conclusions: Higher circulating sST2 concentration at baseline predicts poor clinical outcome in ACS patients.

Download Full-text

Rivaroxaban in patients with atrial fibrillation: from research to real practice (based on REGistry of Long-term AnTithrombotic TherApy-2 (REGATA))

Atherothrombosis Journal ◽

10.21518/2307-1109-2021-1-68-88 ◽

2021 ◽

pp. 68-88

Author(s):

E. S. Kropacheva ◽

E. N. Krivosheeva ◽

E. P. Panchenko

Keyword(s):

Atrial Fibrillation ◽

Acute Coronary Syndrome ◽

Ischemic Stroke ◽

Antithrombotic Therapy ◽

Bleeding Risk ◽

Cardiovascular Death ◽

Cardiovascular Complications ◽

Coronary Syndrome

Introduction. Despite the large evidence base for the use of rivaroxaban, cohort studies are interesting because shows the possibility of anticoagulant therapy in patients with high thromboembolic and bleeding risk and a burden of comorbidity in practice.Aim: to evaluate the efficacy and safety of rivaroxaban therapy in patients with atrial fibrillation in prospective REGATTA registry.Materials and methods. This study is a fragment of a single-center prospective REGATA registry (Registry of Long-term Antithrombotic Therapy (NCT043447187), conducted on the basis of the National Research Center of Cardiology of the Ministry of Health of the Russian Federation. 152 patients with high thromboembolic risk (median CHA2DS2-VASc = 4) received rivaroxaban therapy (median follow-up 1.5 years). The efficacy endpoint was the sum of cardiovascular complications (including cardiovascular death, ischemic stroke, and acute coronary syndrome). The safety endpoint bleedinds BARC types 2-5.Results. The frequency of cardiovascular events (combining cardiovascular death, ischemic stroke and acute coronary syndrome) was 5.8/100 patient-years. The use of a “reduced” dose of rivaroxaban was an independent predictor of the development of fatal cardiovascular complications. The rate of major bleeding was 3.7/100 patient-years, and the rate of clinical relevant bleedings was 19.4 /100 patientyears. The predictors of major/ clinical relevant bleedings were chronic kidney disease with a decrease in creatinine clearance of less than 50 ml/min and the anamneses of major/ clinical relevant bleedings.Conclusion. The main requirement for improving the safety of anticoagulants is follow up, focused in all changes in the cardiovascular and somatic status of the patient during treatment.

Download Full-text